Next Article in Journal / Special Issue
Anti-Cancer Vaccine for HPV-Associated Neoplasms: Focus on a Therapeutic HPV Vaccine Based on a Novel Tumor Antigen Delivery Method Using Endogenously Engineered Exosomes
Previous Article in Journal
Role of Extracellular Vesicles (EVs) in Cell Stress Response and Resistance to Cancer Therapy
Previous Article in Special Issue
Cancer Immunotherapy: Silencing Intracellular Negative Immune Regulators of Dendritic Cells
Open AccessArticle

Treatment Combining CD200 Immune Checkpoint Inhibitor and Tumor-Lysate Vaccination after Surgery for Pet Dogs with High-Grade Glioma

1
Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA
2
Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
3
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA
4
Institute for Health Informatics, University of Minnesota, Minneapolis, MN 55455, USA
5
Department of Neurosurgery, University of Minnesota, Minneapolis, MN 55455, USA
6
Department of Veterinary Clinical Sciences, University of Minnesota, St. Paul, MN 55108, USA;
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(2), 137; https://doi.org/10.3390/cancers11020137
Received: 3 December 2018 / Revised: 14 January 2019 / Accepted: 15 January 2019 / Published: 24 January 2019
(This article belongs to the Special Issue Cancer Vaccines: Research and Applications)
Recent advances in immunotherapy have included inhibition of immune checkpoint proteins in the tumor microenvironment and tumor lysate-based vaccination strategies. We combined these approaches in pet dogs with high-grade glioma. Administration of a synthetic peptide targeting the immune checkpoint protein, CD200, enhanced the capacity of antigen-presenting cells to prime T-cells to mediate an anti-glioma response. We found that in canine spontaneous gliomas, local injection of a canine-specific, CD200-directed peptide before subcutaneous delivery of an autologous tumor lysate vaccine prolonged survival relative to a historical control treated with autologous tumor lysate alone (median survivals of 12.7 months and 6.36 months, respectively). Antigen-presenting cells and T-lymphocytes primed with this peptide suppressed their expression of the inhibitory CD200 receptor, thereby enhancing their ability to initiate immune reactions in a glioblastoma microenvironment replete with the immunosuppressive CD200 protein. These results support consideration of a CD200 ligand as a novel glioblastoma immunotherapeutic agent. View Full-Text
Keywords: glioma; immunotherapy; tumor lysate; dogs glioma; immunotherapy; tumor lysate; dogs
Show Figures

Figure 1

MDPI and ACS Style

Olin, M.R.; Ampudia-Mesias, E.; Pennell, C.A.; Sarver, A.; Chen, C.C.; Moertel, C.L.; Hunt, M.A.; Pluhar, G.E. Treatment Combining CD200 Immune Checkpoint Inhibitor and Tumor-Lysate Vaccination after Surgery for Pet Dogs with High-Grade Glioma. Cancers 2019, 11, 137.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop